Xiongbing Zu

5PUBLICATIONS
2CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 17, 2024
Androgen deprivation therapy, neoadjuvant androgen deprivation therapy, and adjuvant androgen deprivation therapy in patients with locally advanced prostate cancer: a multi-center real-world retrospective study.

Zhenglin Yi, Huihuang Li, Mingyong Li

|Oct 06, 2023
Bladder cancer intrinsic LRFN2 drives anticancer immunotherapy resistance by attenuating CD8+ T cell infiltration and functional transition.

Anze Yu, Jiao Hu, Liangmin Fu

|Jul 06, 2023
S100A5 Attenuates Efficiency of Anti-PD-L1/PD-1 Immunotherapy by Inhibiting CD8+ T Cell-Mediated Anti-Cancer Immunity in Bladder Carcinoma.

Huihuang Li, Jinbo Chen, Zhenghao Li

|Jan 16, 2023
BCAT2 Shapes a Noninflamed Tumor Microenvironment and Induces Resistance to Anti-PD-1/PD-L1 Immunotherapy by Negatively Regulating Proinflammatory Chemokines and Anticancer Immunity.

Zhiyong Cai, Jinbo Chen, Zhengzheng Yu

|Nov 27, 2021
5mC regulator-mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide precision medicine in bladder cancer.

Jiao Hu, Belaydi Othmane, Anze Yu

Pageof 1

Frequent Collaborators

1 joint publications

Zhenhua Chen

1 joint publications

Junhang Luo